News

This is Vivolux’ forum for news and highlights on selected company activities.

Press releases

Exciting events are summarized and commented on in press releases from Vivolux.

 

VLX1570 identified as a potential new treatment for Ewing’s sarcoma

2016-06-02
Memorial Sloan Kettering Cancer Center identifies Vivolux clinical drug candidate VLX1570 as a potential new treatment for Ewing’s sarcoma.

MORE: MSKCC in collaboration with Karolinska Institute demonstrate in a Cancer Research paper preclinical proof of concept for 19S proteasome blocking by Vivolux drug compound VLX1570 as a promising novel therapeutic target for the treatment of Ewing’s sarcoma.

  • NEWS | March 24, 2017

    VLX600 an attractive option for the treatment of solid tumors

    VLX600 an attractive option for the treatment of solid tumors containing heterogeneous populations of proliferating and quiescent cancers cells

    A recent Nature scientific report (Fryknäs et al 2016) shows that VLX600 binds iron and that this property is the underlying mechanisms of VLX600 to inhibit proliferation and to decrease the viability of cancer cells.

    For more, visit R & D Publications.

  • NEWS | June 6, 2016

    Nature publication on the anti-cancer mode-of-action of VLX1570

    Nature publication on the anti-cancer mode-of-action of VLX1570

    Karolinska Institute, Uppsala University, and the Mayo Clinic Cancer Centre in collaboration with Vivolux publish a scientific report in Nature on the mode-of-action of VLX1570.

  • NEWS | June 2, 2016

    VLX1570 identified as a potential new treatment for Ewing’s sarcoma

    Memorial Sloan Kettering Cancer Center identifies Vivolux clinical drug candidate VLX1570 as a potential new treatment for Ewing’s sarcoma.

    MORE: MSKCC in collaboration with Karolinska Institute demonstrate in a Cancer Research paper preclinical proof of concept for 19S proteasome blocking by Vivolux drug compound VLX1570 as a promising novel therapeutic target for the treatment of Ewing’s sarcoma.

News

This is Vivolux’ forum for news and highlights on selected company activities.

Press releases

Exciting events are summarized and commented on in press releases from Vivolux.

  • PRESS RELEASE | May 20, 2016

    VLX600 study closer to completion

    Vivolux announced today that dose level 4 of the ongoing VLX600 study has been successfully completed as part of its phase I/II study. Patient enrollment is now expanding to dose level 5, 90 mg of VLX600.

    VLX600 is one of the company's promising first-in-class projects. Researchers at Vivolux have discovered a novel cancer drug target. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization – areas that are insensitive to conventional cancer therapeutics.

    VLX600, whose mode of action was published in the journal Nature Communications in 2014, is designed to increase the efficacy of radiotherapy and to kill cancer cells that survive traditional chemotherapy. The study is being conducted in collaboration with Mayo Clinic Cancer Centers in patients with solid tumors who are no longer responding to conventional cancer treatment. The aim is to determine the optimal dose for current and future clinical studies. Up to six dose levels have been planned for in the study protocol.

    In solid tumors there are areas with poor vascular supply where cancer cells divide more slowly due to a lack of oxygen and nutrients. Cancer cells in these areas enter a sleeping state. The 'sleeping cells' begin proliferating between therapy cycles after treatment with radiotherapy or conventional chemotherapy, resulting in regrowth of tumors. Regrowth of this nature between therapy cycles is a major clinical problem. Vivolux’s drug candidate, VLX600, kills ‘sleeping cancer cells’ by cutting off the power supply in the cells’ power plants – the mitochondria.

    Hans Rosén, CEO and founder, states: "Drug exposure data indicate that we are close to determining the optimal dose for VLX600 treatment of cancer patients. We are very grateful to our colleagues at the Mayo Clinic Cancer Center and their commitment to carrying out the study. There is a considerable medical need for new cancer drugs. VLX600 represents a first-in-class molecule within a new mechanism of action. This is a promising new concept in cancer treatment.”

    Joachim Gullbo, MD, PhD, and Chief Medical Officer at Vivolux, said: "The conclusion that treatment with VLX600 is tolerable and without any unsuspected adverse events at the first dose levels is highly encouraging, and we are looking forward to continuing the study at the next dose level."

    Vivolux was founded in Sweden in 2004 with a focus on the development of novel cancer drugs based on phenotypic models, where the unique behavior of malignant cells under specific conditions is utilized to identify new targets and molecules acting on these targets. Working in close collaboration with research groups at Uppsala University and the Karolinska Institute, Vivolux has developed a unique and comprehensive system for preclinical analysis of cancer drugs, including tests on primary cultures of human cancer cells, cells grown in three-dimensional aggregates and methods for molecular investigation of mechanism of action. Several drug candidates have been identified and optimized and the results from these investigations have been published in international scientific journals. Two novel drugs with new mechanisms of action for cancer treatment are currently undergoing clinical investigation in collaboration with leading cancer institutes in the USA. In 2014, Vivolux Inc. was established in the USA. The Swedish office is located at the AZ BioVentureHub in Gothenburg.

    For further information, please contact:

    Hans Rosén, CEO, hans.rosen@vivolux.com Phone: +1 202 400 1470
    Stig Linder, CSO, Professor of Pharmacology, Department of Medicine and Health, Linköping University, Professor of Cancer Pharmacology, Department of Oncology and Pathology, Karolinska Institute, Stockholm
    Stig.Linder@liu.se, Stig.Linder@ki.se Phone: +46 704 841275

    Vivolux Inc.: 20130 Lakeview Center Plaza, Suite 400, Ashburn, VA 20147, USA
    Phone: +1 703-840-5474
    Vivolux AB: AZ BioVentureHub SE-431 83 Mölndal, Sweden,
    www.vivolux.com

     

  • PRESS RELEASE | September 17, 2015

    Progress for Vivolux drug candidate VLX1570

    Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the first patient in its ongoing Phase I/II study has successfully completed treatment at the third dose level of the drug candidate VLX1570.

    Vivolux has developed a drug which through a newly discovered mechanism blocks the proteasome, the cell degradation 'machine' for defective proteins.

    Large amounts of defective proteins form in tumor cells, making them vulnerable to disruption of proteasome function. The new mechanism of action by VLX1570 has been shown to inhibit tumor growth and prolong survival in various preclinical models of multiple myeloma, including those that exhibit resistance to other cancer treatments.

    The clinical study is being conducted in collaboration with the Memorial Sloan-Kettering Cancer Center in New York and the Dana-Farber Cancer Institute at Harvard Medical School in Boston, MA. The phase I part of the study is designed to determine the safety and maximum tolerated dose of VLX1570 in patients with multiple myeloma who are no longer benefiting from conventional cancer treatment.  The phase II part of the study is to investigate the clinical efficacy of VLX1570 in this patient population.

    Proteasome inhibitors (e.g. bortezomib/Velcade®) have been available for the treatment of malignant diseases (e.g. multiple myeloma and mantle cell lymphoma) for some years although development of resistance to this therapy is a major clinical problem. As preclinical research has shown, the novel drug candidate VLX1570 acts on the proteasome through a new mechanism of action. By blocking the initiation process that regulates the breakdown of defective protein, the cancer cells are forced into apoptosis – programmed cell death. There is a significant medical need in multiple myeloma therapy, especially for patients who have become resistant to currently available cancer treatment such as bortezomib (Velcade®).

    Preclinical research has generated considerable scientific interest and results have been published in renowned scientific journals such as Nature Medicine and Blood. This is the second drug candidate developed by Vivolux to proceed into the clinical phase. VLX600 is the company’s first drug candidate to be evaluated at the clinical phase. The study is being conducted in collaboration with the Mayo Clinic Cancer Centers in the USA.

    Hans Rosén, CEO and founder, said: "We are very excited about the progress in the VLX1570 study. We have a strong scientific basis for VLX1570 and the expectations are high that this new approach to treating cancer will make a significant difference for cancer patients. We look forward to establishing the therapeutic dose and to evaluating VLX1570 on multiple myeloma patients.

    Joachim Gullbo, MD, PhD and Chief Medical Officer at Vivolux, said: "VLX1570 is Vivolux's second drug candidate to reach first-in-human evaluation. VLX1570 represents a new molecular mechanism of action of an already proven pharmacologically important target for cancer treatment, the proteasome. We are very excited about the opportunity to cooperate with leading clinicians who are working to improve the treatment of critically ill patients. This is a new and promising concept for cancer treatment.”

    Vivolux was founded in Sweden in 2004 with a focus on the development of novel cancer drugs based on phenotypic models, where the unique behavior of malignant cells under specific conditions is utilized to identify new targets and molecules acting on these targets. Working in close collaboration with research groups at Uppsala University and the Karolinska Institute, Vivolux has developed a unique and comprehensive system for preclinical analysis of cancer drugs, including tests on primary cultures of human cancer cells, cells grown in three-dimensional aggregates and methods for molecular investigation of mechanism of action. Several drug candidates have been identified and optimized and the results from these investigations have been published in international scientific journals. Two novel drugs with new mechanisms of action for cancer treatment are currently undergoing clinical investigation in collaboration with leading cancer institutes in the USA. In 2014, the Vivolux head office was established in Ashburn, Virginia, USA. The Swedish office is located at the AZ BioVentureHub in Gothenburg.

    For further information, please contact:
    Hans Rosén,
    CEO, hans.rosen@vivolux.com, phone: +1 202 400 1470
    Stig Linder, CSO, Professor of Pharmacology, Department of Medicine and Health, Linköping University, Professor of Cancer Pharmacology, Department of Oncology and Pathology, Karolinska Institute, Stockholm
    Stig.Linder@liu.se, Stig.Linder@ki.se +46 704 841275 

    Vivolux Inc.: 20130 Lakeview Center Plaza, Suite 400, Ashburn, VA 20147, USA
    Phone: +1 703-840-5474

    Vivolux AB: AZ BioVentureHub SE-431 83 Mölndal, Sweden
    www.vivolux.com

    This press release is also downloadable as PDF.

  • PRESS RELEASE | April 16, 2015

    Promising progress in Vivolux’ VLX600 Study

    Promising progress in Vivolux VLX600 Study - The first dose level of the ongoing VLX600 study has successfully been accomplished in its phase I/II-study.

    VLX600 is one of the company's promising projects, which was recently published in the journal Nature Communications. Researchers at Vivolux have discovered a novel cancer drug target. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization – areas that cannot be reached by conventional cancer therapeutics.

    VLX600 is designed to increase the efficacy of radiotherapy and to kill cancer cells that survive traditional chemotherapy. The study is being conducted in collaboration with Mayo Clinic Cancer Centers in patients with solid tumors who no longer respond to conventional cancer treatment. The aim is to determine the optimal dose for the current and future clinical studies. VLX600 is designed to increase the efficacy of radiotherapy and to kill cancer cells that survive traditional chemotherapy.

    In solid tumors, there are areas with poor vascular supply where cancer cells divide more slowly due to a lack of oxygen and nutrients. Cancer cells in these areas enter a sleeping state. The 'sleeping cells' start proliferating between therapy cycles after treatment with radiotherapy or conventional chemotherapy, resulting in regrowth of tumors. Such regrowth between therapy cycles is a major clinical problem. Vivolux’ drug candidate, VLX600, kills ‘sleeping cancer cells’ by strangling the power supply in the cells’ power plants – the mitochondria.

    Hans Rosén, CEO and founder, stated. “It's great that after many years of research, we have the privilege to treat patients. The fact that this research has attracted interest at leading cancer centers in the USA is solid recognition to the quality of our scientists and their work. There is a significant medical need for new cancer drugs and VLX600 provides the ability to treat cancer patients in a new way.”

    Joachim Gullbo, MD, PhD, and Chief Medical Officer at Vivolux, said: "VLX600 is the first candidate in a novel class of cancer drugs. We are very excited about the opportunity to take it from bench to bedside".

    Vivolux was founded in Sweden in 2004. The Swedish office is located at the AZ BioVentureHub in Gothenburg. In 2014, the Vivolux head office was established in Ashburn, Virginia, USA. Vivolux focuses on the development of novel cancer drugs based on phenotypic models, where the unique behavior of malignant cells under specific conditions is utilized to identify new targets and molecules acting on these 2 targets. Working in close collaboration with research groups at Uppsala University and the Karolinska Institute, Vivolux has developed a unique and comprehensive system for preclinical analysis of cancer drugs, including tests on primary cultures of human cancer cells, cells grown in three-dimensional aggregates and methods for molecular investigation of mechanism of action. Several drug candidates have been identified and optimized and the results from these investigations have been published in international scientific journals. Two novel drugs with new mechanisms of action for cancer treatment are currently in clinical investigation in collaboration with leading cancer centers in the USA.

    For further information, please contact:
    Hans Rosén, CEO, hans.rosen@vivolux.com, phone: +1 202 400 1470
    Stig Linder, stig.linder@ki.se, Professor of Experimental Oncology, Department of Oncology and Pathology, Karolinska Institute, phone: +46 (0)704 841275

    Vivolux Inc: 20130 Lakeview Center Plaza, Suite 400, Ashburn, VA 20147, USA
    Phone: +1 703-840-5474
    Vivolux AB: AZ BioVentureHub SE-431 83 Mölndal, Sweden.
    www.vivolux.com

    This press release is also downloadable as PDF.